| Pneumonitis in non–small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors K Suresh, KR Voong, B Shankar, PM Forde, DS Ettinger, KA Marrone, ... Journal of Thoracic Oncology 13 (12), 1930-1939, 2018 | 349 | 2018 |
| Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities K Suresh, J Naidoo, CT Lin, S Danoff Chest 154 (6), 1416-1423, 2018 | 301 | 2018 |
| Design, data analysis and sampling techniques for clinical research K Suresh, SV Thomas, G Suresh Annals of Indian Academy of Neurology 14 (4), 287-290, 2011 | 187 | 2011 |
| Lung Circulation K Suresh, L Shimoda Comprehensive Physiology 6 (2), 897-943, 2016 | 149 | 2016 |
| Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy K Suresh, KJ Psoter, KR Voong, B Shankar, PM Forde, DS Ettinger, ... Journal of Thoracic Oncology 14 (3), 494-502, 2019 | 133 | 2019 |
| The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis K Suresh, J Naidoo, Q Zhong, Y Xiong, J Mammen, MV De Flores, ... The Journal of clinical investigation 129 (10), 4305-4315, 2019 | 128 | 2019 |
| Hydrogen peroxide-induced calcium influx in lung microvascular endothelial cells involves TRPV4 K Suresh, L Servinsky, J Reyes, S Baksh, C Undem, M Caterina, ... American Journal of Physiology-Lung Cellular and Molecular Physiology 309 …, 2015 | 111 | 2015 |
| Relationship between prior radiotherapy and checkpoint-inhibitor pneumonitis in patients with advanced non–small-cell lung cancer KR Voong, SZ Hazell, W Fu, C Hu, CT Lin, K Ding, K Suresh, J Hayman, ... Clinical lung cancer 20 (4), e470-e479, 2019 | 102 | 2019 |
| A multidisciplinary toxicity team for cancer immunotherapy–related adverse events J Naidoo, J Zhang, EJ Lipson, PM Forde, K Suresh, KF Moseley, S Mehta, ... Journal of the National Comprehensive Cancer Network 17 (6), 712-720, 2019 | 84 | 2019 |
| Reactive oxygen species induced Ca2+ influx via TRPV4 and microvascular endothelial dysfunction in the SU5416/hypoxia model of pulmonary arterial hypertension K Suresh, L Servinsky, H Jiang, Z Bigham, X Yun, C Kliment, J Huetsch, ... American Journal of Physiology-Lung Cellular and Molecular Physiology, 2018 | 78 | 2018 |
| Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled … JJ Solomon, SK Danoff, FA Woodhead, S Hurwitz, R Maurer, I Glaspole, ... The Lancet Respiratory Medicine 11 (1), 87-96, 2023 | 77 | 2023 |
| Chronic immune checkpoint inhibitor pneumonitis J Naidoo, TR Cottrell, EJ Lipson, PM Forde, PB Illei, LB Yarmus, ... Journal for immunotherapy of cancer 8 (1), 2020 | 73 | 2020 |
| Steroid-refractory PD-(L) 1 pneumonitis: incidence, clinical features, treatment, and outcomes A Balaji, M Hsu, CT Lin, J Feliciano, K Marrone, JR Brahmer, PM Forde, ... Journal for immunotherapy of cancer 9 (1), 2021 | 64 | 2021 |
| Pulmonary toxicity of systemic lung cancer therapy K Long, K Suresh Respirology 25, 72-79, 2020 | 55 | 2020 |
| Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology J Naidoo, C Murphy, MB Atkins, JR Brahmer, S Champiat, D Feltquate, ... Journal for immunotherapy of cancer 11 (3), 2023 | 34 | 2023 |
| Pneumonitis From Anti--PD-1/PD-L1 Therapy. A Balaji, F Verde, K Suresh, J Naidoo Oncology (08909091) 31 (10), 2017 | 33 | 2017 |
| Checkpoint inhibitor pneumonitis: mechanisms, characteristics, management strategies, and beyond JE Reuss, K Suresh, J Naidoo Current oncology reports 22, 1-10, 2020 | 31 | 2020 |
| A nonapoptotic endothelial barrier-protective role for caspase-3 K Suresh, K Carino, L Johnston, L Servinsky, CE Machamer, TM Kolb, ... American Journal of Physiology-Lung Cellular and Molecular Physiology 316 (6 …, 2019 | 31 | 2019 |
| Lower Survival in Patients Who Develop Pneumonitis Following Immunotherapy for Lung Cancer. K Suresh, J Naidoo Clinical lung cancer 21 (3), e169-e170, 2019 | 30 | 2019 |
| Regulation of smooth muscle cell proliferation by NADPH oxidases in pulmonary hypertension JC Huetsch, K Suresh, LA Shimoda Antioxidants 8 (3), 56, 2019 | 29 | 2019 |
